20/20 Biolabs, Inc.

The company develops and commercializes AI-powered blood tests for early detection of cancers and chronic diseases through its OneTest brand, which includes a multi-cancer early detection test based on protein tumor markers and a test measuring inflammatory biomarkers associated with chronic disease. The tests are processed in the company's CLIA-licensed laboratory and sold through both business-to-business channels—including firefighter departments, occupational health practitioners, and retail clinics—and direct-to-consumer partnerships with supermarket chains and employers, with pricing positioned as affordable relative to competing cancer screening tests. The company also operates CLIAx, a shared laboratory facility for diagnostics start-ups launching novel tests in the U.S., and maintains a legacy business in bioterrorism detection kits that serve emergency responders.